{"success":true,"data":{"pressRelease":{"id":"159127","rtpr_id":"nPrejHfbZa-20261002","ticker":"4108","exchange":"TWSE","all_tickers":["4108"],"title":"PhytoHealth CEO Angel Lee Recognized for Driving the Advancement of World's First Prescription Drug for Cancer-Related Fatigue","author":"PR Newswire","published_at":"2026-10-02T08:11:44.715Z","article_body":"PhytoHealth CEO Angel Lee Recognized for Driving the Advancement of World's\nFirst Prescription Drug for Cancer-Related Fatigue\nPR Newswire\n\nTAIPEI, Oct. 2, 2026\n\nRecognition highlights PhytoHealth's work in advancing PG2(®), Taiwan's first\napproved botanical new drug, and raising clinical awareness of cancer-related\nfatigue\n\nTAIPEI, Oct. 2, 2026 /PRNewswire/ -- PhytoHealth Corporation CEO Angel Lee has\nbeen named one of Taiwan's 27th Ten Outstanding Young Women. The prestigious\nnational recognition highlights her leadership in advancing PG2(® )Lyo.\nInjection—the world's first prescription drug approved specifically for\nmoderate to severe cancer-related fatigue (CRF)—and her contributions to\nbotanical drug development and cancer supportive care.\n\n\nDeveloped from refined polysaccharides of Astragalus membranaceus, a medicinal\nplant documented in the WHO Monographs on Selected Medicinal Plants, PG2(®)\nis also Taiwan's first approved botanical new drug. PG2(®) is used across\nmedical institutions in Taiwan for the management of cancer-related fatigue\nand is covered by Taiwan's National Health Insurance (NHI) for eligible breast\ncancer patients. PhytoHealth continues to build clinical evidence around its\nproprietary refined Astragalus polysaccharide (rAPS(®)) platform and explore\nits broader potential in cancer supportive care.\n\nCRF is a debilitating condition distinct from ordinary tiredness and can\naffect patients throughout cancer treatment. Yet it has historically been\nunderrecognized and undertreated. Beyond developing PG2(®), PhytoHealth has\nworked with Taiwan's medical community to help shift CRF from an\noften-overlooked aspect of the cancer experience toward a condition that is\nmore actively recognized and managed in clinical care. These efforts\ncontributed to the development of Taiwan's first clinical guidelines for\ncancer-related fatigue.\n\nBuilding on PG2(®)'s established clinical use and regulatory foundation in\nTaiwan, PhytoHealth is actively seeking international pharmaceutical and\nhealthcare partners to advance the global development of PG2(®) and its\nbotanical drug platform.\n\n\"This recognition is not only a personal honor, but also a responsibility,\"\nLee said. \"Our goal is to turn scientific research into meaningful benefits\nfor patients. We will continue working with medical and industry partners\naround the world to advance cancer supportive care and bring Taiwan's\nbiotechnology innovation to the global healthcare community.\"\n\nLee and fellow honorees were recognized for their achievements across\nprofessional fields and contributions to society.\n\nLee holds a bachelor's degree in accounting from National Taiwan University\nand an MBA from Carnegie Mellon University. Before taking on leadership roles\nin biotechnology, she gained professional experience at Deloitte and Johnson &\nJohnson's Janssen pharmaceutical business.\n\nAbout PhytoHealth Corporation\n\nPhytoHealth Corporation is a Taiwan-based biotechnology company focused on the\nresearch, development and commercialization of innovative therapeutics, with\nparticular expertise in botanical drug development. Its portfolio includes\nPG2(®) Lyo. Injection for cancer-related fatigue and Oraphine(®), an oral\nanalgesic developed for the management of moderate to severe pain. Building on\nits refined Astragalus polysaccharide (rAPS(®)) platform and broader drug\ndevelopment capabilities, PhytoHealth continues to advance clinical research\nand pursue international partnerships to bring Taiwan-developed healthcare\ninnovations to global markets.\n\nView original content to download\nmultimedia:https://www.prnewswire.co.uk/news-releases/phytohealth-ceo-angel-lee-recognized-for-driving-the-advancement-of-worlds-first-prescription-drug-for-cancer-related-fatigue-302897043.html\n\n\n\nAlison.Tsai, alison.tsai@phytohealth.com.tw, +886 2-27136227 #2315\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS2001389/PKH.jpg?id=OA2984331\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPrejHfbZa-20261002","title":"PhytoHealth CEO Angel Lee Recognized for Driving the Advancement of World's First Prescription Drug for Cancer-Related Fatigue","author":"PR Newswire","ticker":"4108","created":"2026-10-02T08:11:44.715Z","tickers":["4108"],"exchange":"TWSE","article_body":"PhytoHealth CEO Angel Lee Recognized for Driving the Advancement of World's\nFirst Prescription Drug for Cancer-Related Fatigue\nPR Newswire\n\nTAIPEI, Oct. 2, 2026\n\nRecognition highlights PhytoHealth's work in advancing PG2(®), Taiwan's first\napproved botanical new drug, and raising clinical awareness of cancer-related\nfatigue\n\nTAIPEI, Oct. 2, 2026 /PRNewswire/ -- PhytoHealth Corporation CEO Angel Lee has\nbeen named one of Taiwan's 27th Ten Outstanding Young Women. The prestigious\nnational recognition highlights her leadership in advancing PG2(® )Lyo.\nInjection—the world's first prescription drug approved specifically for\nmoderate to severe cancer-related fatigue (CRF)—and her contributions to\nbotanical drug development and cancer supportive care.\n\n\nDeveloped from refined polysaccharides of Astragalus membranaceus, a medicinal\nplant documented in the WHO Monographs on Selected Medicinal Plants, PG2(®)\nis also Taiwan's first approved botanical new drug. PG2(®) is used across\nmedical institutions in Taiwan for the management of cancer-related fatigue\nand is covered by Taiwan's National Health Insurance (NHI) for eligible breast\ncancer patients. PhytoHealth continues to build clinical evidence around its\nproprietary refined Astragalus polysaccharide (rAPS(®)) platform and explore\nits broader potential in cancer supportive care.\n\nCRF is a debilitating condition distinct from ordinary tiredness and can\naffect patients throughout cancer treatment. Yet it has historically been\nunderrecognized and undertreated. Beyond developing PG2(®), PhytoHealth has\nworked with Taiwan's medical community to help shift CRF from an\noften-overlooked aspect of the cancer experience toward a condition that is\nmore actively recognized and managed in clinical care. These efforts\ncontributed to the development of Taiwan's first clinical guidelines for\ncancer-related fatigue.\n\nBuilding on PG2(®)'s established clinical use and regulatory foundation in\nTaiwan, PhytoHealth is actively seeking international pharmaceutical and\nhealthcare partners to advance the global development of PG2(®) and its\nbotanical drug platform.\n\n\"This recognition is not only a personal honor, but also a responsibility,\"\nLee said. \"Our goal is to turn scientific research into meaningful benefits\nfor patients. We will continue working with medical and industry partners\naround the world to advance cancer supportive care and bring Taiwan's\nbiotechnology innovation to the global healthcare community.\"\n\nLee and fellow honorees were recognized for their achievements across\nprofessional fields and contributions to society.\n\nLee holds a bachelor's degree in accounting from National Taiwan University\nand an MBA from Carnegie Mellon University. Before taking on leadership roles\nin biotechnology, she gained professional experience at Deloitte and Johnson &\nJohnson's Janssen pharmaceutical business.\n\nAbout PhytoHealth Corporation\n\nPhytoHealth Corporation is a Taiwan-based biotechnology company focused on the\nresearch, development and commercialization of innovative therapeutics, with\nparticular expertise in botanical drug development. Its portfolio includes\nPG2(®) Lyo. Injection for cancer-related fatigue and Oraphine(®), an oral\nanalgesic developed for the management of moderate to severe pain. Building on\nits refined Astragalus polysaccharide (rAPS(®)) platform and broader drug\ndevelopment capabilities, PhytoHealth continues to advance clinical research\nand pursue international partnerships to bring Taiwan-developed healthcare\ninnovations to global markets.\n\nView original content to download\nmultimedia:https://www.prnewswire.co.uk/news-releases/phytohealth-ceo-angel-lee-recognized-for-driving-the-advancement-of-worlds-first-prescription-drug-for-cancer-related-fatigue-302897043.html\n\n\n\nAlison.Tsai, alison.tsai@phytohealth.com.tw, +886 2-27136227 #2315\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS2001389/PKH.jpg?id=OA2984331\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-02T08:11:44.76020846Z","server_sent_at_ms":1790928704760},"received_at":"2026-10-02T08:11:44.810Z","source_url":null},"analysis":{"id":"147738","press_release_id":"159127","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"PhytoHealth CEO Angel Lee was named one of Taiwan's 27th Ten Outstanding Young Women, honoring her role in advancing PG2®.\n\nPG2® is the world's first prescription drug approved for moderate to severe cancer-related fatigue and Taiwan's first approved botanical new drug, covered by Taiwan NHI for eligible breast cancer patients.\n\nThe company says it is seeking international partners to develop PG2® and its botanical platform globally, but this release contains no financial or regulatory developments.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"CEO award profile -- suppress for alerting; background only."},"keyFigures":{},"quotedText":"This recognition is not only a personal honor, but also a responsibility","namedEntities":{"people":[{"name":"Angel Lee","role":"CEO"},{"name":"Alison.Tsai","role":"media contact"}],"products":["PG2® Lyo. Injection","Oraphine®","rAPS®"],"companies":[{"name":"PhytoHealth Corporation","ticker":"4108"},{"name":"Deloitte","relationship":"prior employer"},{"name":"Johnson & Johnson","relationship":"prior employer (Janssen)"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Personal recognition award for the CEO; no financial, regulatory, or pipeline news."},"tickerRelevance":{"others":[],"primary":"4108"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"executive-recognition-award","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"PhytoHealth CEO Angel Lee was named one of Taiwan's 27th Ten Outstanding Young Women, honoring her role in advancing PG2®.\n\nPG2® is the world's first prescription drug approved for moderate to severe cancer-related fatigue and Taiwan's first approved botanical new drug, covered by Taiwan NHI for eligible breast cancer patients.\n\nThe company says it is seeking international partners to develop PG2® and its botanical platform globally, but this release contains no financial or regulatory developments.","key_figures":{},"named_entities":{"people":[{"name":"Angel Lee","role":"CEO"},{"name":"Alison.Tsai","role":"media contact"}],"products":["PG2® Lyo. Injection","Oraphine®","rAPS®"],"companies":[{"name":"PhytoHealth Corporation","ticker":"4108"},{"name":"Deloitte","relationship":"prior employer"},{"name":"Johnson & Johnson","relationship":"prior employer (Janssen)"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-02T08:11:51.409Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"small-cap","eventGravity":"executive-recognition-award","issuerAuthored":true}},"durationMs":6585,"modelName":"glm-5.3-flashx"}}